GE HealthCare Technologies Inc. (GEHC) KPIs and segments
Close on Nov 18, 2026Market cap $37.83BP/E 17.6Yield 0.17%
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của GE HealthCare Technologies · năm tài chính kết thúc December 31 (Calendar Fiscal Year; FY2025 ended December 31, 2025; Q3 2026 ended September 30, 2026)
Nhìn nhanh KPI của GE HealthCare Technologies: 48 chỉ số vận hành, trong đó có Total Company Book-to-Bill Ratio (times), Total Ending Backlog và Total Remaining Performance Obligations — RPO, lấy từ 111 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
AIS($M) | 3,873 | 3,771 | 3,649 | 3,493 | |||||||||
Imaging($M) | 2,299 | 2,552 | 2,349 | 2,204 | 2,140 | 2,393 | 2,229 | 2,171 | 2,062 | 2,392 | |||
AVS($M) | 1,341 | 1,525 | 1,301 | 1,289 | 1,239 | 1,439 | 1,216 | 1,249 | 1,227 | 1,382 | |||
PDx($M) | 846 | 843 | 770 | 790 | 749 | 729 | 632 | 646 | 625 | 639 | 599 | 591 | |
PCS($M) | 793 | 675 | 704 | 824 | 731 | 778 | 753 | 827 | 779 | 772 | 747 | 827 | |
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)1 | |||||||||||||
Product($M) | 3,602 | 3,416 | 3,345 | 3,906 | 3,375 | 3,263 | 3,117 | 3,621 | 3,201 | 3,207 | 3,045 | 3,597 | |
Service($M) | 1,911 | 1,878 | 1,786 | 1,792 | 1,769 | 1,743 | 1,660 | 1,698 | 1,662 | 1,632 | 1,605 | 1,609 | |
AIS($M) | 1,564 | 1,517 | 1,431 | 1,387 | |||||||||
Imaging($M) | 757 | 838 | 786 | 734 | 787 | 888 | 842 | 778 | 724 | ||||
AVS($M) | 679 | 786 | 646 | 652 | 641 | 771 | 608 | 638 | 628 | ||||
PDx($M) | 428 | 421 | 364 | 389 | 365 | 358 | 338 | 331 | 313 | 325 | 304 | ||
PCS($M) | 269 | 181 | 223 | 286 | 228 | 271 | 272 | 322 | 293 | 292 | 287 | ||
Product($M) | 1,229 | 1,199 | 1,062 | 1,356 | 1,105 | 1,103 | 1,154 | 1,395 | 1,168 | 1,162 | 1,078 | 1,329 | |
Service($M) | 995 | 980 | 915 | 905 | 885 | 880 | 858 | 880 | 857 | 840 | 823 | 827 | |
Remaining performance obligations (RPO)($M) | 16,113 | 16,118 | 15,828 | 15,729 | 15,096 | 15,304 | 14,879 | 14,563 | 14,531 | 14,313 | |||
Total Company Book-to-Bill Ratio (times)(×)2 | 1.03 | 1.15 | 1.07 | 1.06 | 1.06 | 1.07 | 1.09 | 1.09 | 1.04 | 1.06 | 1.03 | 1.05 | |
Organic Orders Growth (% YoY)(%) | 4.0% | 11.1% | 1.1% | 2.0% | 6.0% | 3.0% | 10.0% | 6.0% | 1.0% | 3.0% | 1.0% | 3.0% | |
Organic Orders Growth — Exact One-Decimal Series (% YoY)(%) | 4.0% | 11.1% | 1.1% | 2.0% | 5.7% | 10.3% | 5.6% | ||||||
Total Ending Backlog ($B)1 | 23.70 | 23.90 | 21.80 | 21.80 | 21.20 | 21.30 | 19.80 | ||||||
Total Backlog Year-over-Year Dollar Change ($B) | 2.50 | 2.60 | 1.20 | 2.00 | 2.20 | 0.70 | |||||||
Total Remaining Performance Obligations — RPO ($M)($M)2 | 16,113 | 16,118 | 15,828 | 15,729 | 15,096 | 15,304 | 14,879 | 14,491 | 14,563 | 14,531 | 14,313 | 14,655 | |
Products Remaining Performance Obligations ($M)($M) | 5,352 | 5,180 | 5,140 | 5,001 | 4,899 | 4,805 | 4,599 | 4,755 | 4,808 | 4,648 | 4,742 | 4,930 | |
Services Remaining Performance Obligations ($M)($M) | 10,761 | 10,939 | 10,688 | 10,728 | 10,197 | 10,500 | 10,280 | 9,737 | 9,756 | 9,883 | 9,570 | 9,725 | |
Advanced Imaging & Solutions (AIS) Segment Revenue ($M)($M)9 | 3,873 | 3,771 | 3,640 | 4,077 | 3,649 | 3,493 | 3,379 | 3,833 | 3,445 | 3,419 | 3,289 | ||
Radiology Sub-Segment Revenue — MR, CT, Molecular Imaging, X-Ray & Women's Health ($M)($M) | 2,463 | 2,388 | 2,299 | 2,552 | 2,349 | 2,204 | 2,140 | 2,393 | 2,229 | 2,171 | 2,062 | 2,392 | |
Procedural Guidance Sub-Segment Revenue — Interventional & Surgical Visualization ($M)($M) | 772 | 715 | 719 | 789 | 662 | 660 | 641 | 744 | 647 | 668 | 651 | 727 | |
Specialized Ultrasound Sub-Segment Revenue ($M)($M) | 639 | 668 | 622 | 735 | 638 | 630 | 598 | 696 | 569 | 581 | 576 | 655 | |
AIS Reported Revenue Growth (% YoY)(%) | 6.1% | 7.9% | 7.7% | 6.4% | 5.9% | 2.2% | 2.7% | ||||||
AIS Organic Revenue Growth (% YoY)(%) | 4.5% | 5.0% | 1.8% | 4.9% | 4.7% | 1.4% | 4.1% | ||||||
AIS Organic Revenue Base ($M)($M) | 3,814 | 3,668 | 3,440 | 4,020 | 3,608 | 3,468 | 3,423 | ||||||
AIS Foreign Exchange Revenue Impact ($M)($M) | -8 | 41 | 140 | 56 | 41 | 25 | -57 | ||||||
AIS Acquisitions & Divestitures Revenue Contribution ($M)($M) | 68 | 62 | 60 | 1 | 0 | 0 | 14 | ||||||
AIS Segment EBIT ($M)($M)4 | 593 | 525 | 479 | 641 | 512 | 455 | 460 | 676 | 518 | 463 | 422 | ||
AIS Cost of Sales ($M)($M) | 2,309 | 2,254 | 2,204 | 2,452 | 2,218 | 2,106 | 1,951 | 2,173 | 1,995 | 2,004 | 1,936 | ||
AIS Operating & Other Segment Expenses ($M)($M) | 972 | 992 | 957 | 984 | 920 | 932 | 968 | 984 | 932 | 952 | 931 | ||
AIS Total Segment Costs & Expenses ($M)($M) | 3,281 | 3,246 | 3,161 | 3,436 | 3,138 | 3,039 | 2,919 | 3,157 | 2,927 | 2,956 | 2,867 | ||
AIS Segment Depreciation & Amortization ($M)($M) | 67 | 67 | 72 | 73 | 73 | 75 | 75 | 77 | 82 | 83 | 86 | ||
Patient Care Solutions (PCS) Segment Revenue ($M)($M)8 | 793 | 675 | 704 | 825 | 731 | 778 | 753 | 827 | 779 | 772 | 747 | 827 | |
Monitoring Solutions Sub-Segment Revenue — Patient Monitoring & Diagnostic Cardiology ($M)($M) | 584 | 503 | 519 | 577 | 544 | 578 | 556 | 574 | 556 | 538 | 527 | 595 | |
Life Support Solutions Sub-Segment Revenue — Anesthesia, Respiratory & Maternal-Infant Care ($M)($M) | 209 | 172 | 185 | 247 | 187 | 200 | 197 | 253 | 223 | 235 | 220 | 232 | |
PCS Reported Revenue Growth (% YoY)(%) | 8.5% | -13.3% | -6.5% | -0.3% | -6.2% | 0.8% | 0.8% | ||||||
PCS Organic Revenue Growth (% YoY)(%) | 8.8% | -13.5% | -8.1% | -1.1% | -6.7% | 0.4% | 1.7% | ||||||
PCS Organic Revenue Base ($M)($M) | 795 | 673 | 692 | 818 | 727 | 775 | 760 | ||||||
PCS Foreign Exchange Revenue Impact ($M)($M) | -2 | 2 | 12 | 7 | 4 | 3 | -7 | ||||||
PCS Acquisitions & Divestitures Revenue Contribution ($M)($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
PCS Segment EBIT ($M)($M)5 | 68 | -26 | 10 | 74 | 27 | 60 | 48 | 106 | 82 | 78 | 81 | 107 | |
PCS Segment EBIT Margin (%)(%) | 8.6% | -3.8% | 1.4% | 9.0% | 3.7% | 7.7% | 6.4% | 12.8% | 10.5% | 10.1% | 10.8% | ||
PCS Cost of Sales ($M)($M) | 524 | 494 | 481 | 538 | 503 | 507 | 481 | 505 | 486 | 480 | 460 | ||
PCS Operating & Other Segment Expenses ($M)($M) | 200 | 207 | 213 | 212 | 201 | 212 | 224 | 216 | 211 | 215 | 206 | ||
PCS Total Segment Costs & Expenses ($M)($M) | 725 | 700 | 694 | 750 | 703 | 719 | 705 | 721 | 697 | 694 | 666 | ||
PCS Segment Depreciation & Amortization ($M)($M) | 13 | 13 | 13 | 13 | 14 | 13 | 13 | 14 | 13 | 14 | 15 | ||
Pharmaceutical Diagnostics (PDx) Segment Revenue — Contrast Media & Molecular Imaging Agents ($M)($M)6 | 846 | 843 | 770 | 790 | 749 | 729 | 632 | 646 | 625 | 639 | 599 | 591 | |
PDx Reported Revenue Growth (% YoY)(%) | 13.0% | 15.6% | 21.8% | 22.3% | 19.8% | 14.1% | 5.6% | ||||||
PDx Organic Revenue Growth (% YoY)(%) | 13.8% | 14.6% | 9.7% | 12.7% | 9.6% | 5.0% | 7.9% | ||||||
PDx Organic Revenue Base ($M)($M) | 852 | 835 | 693 | 726 | 683 | 669 | 646 | ||||||
PDx Foreign Exchange Revenue Impact ($M)($M) | -6 | 8 | 76 | 13 | 15 | 7 | -14 | ||||||
PDx Acquisitions & Divestitures Revenue Contribution ($M)($M) | 0 | 0 | 0 | 51 | 51 | 53 | 0 | ||||||
PDx Segment EBIT ($M)($M)5 | 253 | 250 | 197 | 234 | 220 | 213 | 205 | 212 | 193 | 200 | 178 | 192 | |
PDx Segment EBIT Margin (%)(%) | 29.9% | 29.7% | 25.6% | 29.6% | 29.4% | 29.2% | 32.4% | 32.9% | 30.9% | 31.3% | 29.7% | ||
PDx Cost of Sales ($M)($M) | 418 | 422 | 406 | 400 | 384 | 371 | 294 | 314 | 312 | 314 | 295 | ||
PDx Operating & Other Segment Expenses ($M)($M) | 174 | 171 | 167 | 156 | 145 | 144 | 133 | 119 | 120 | 125 | 126 | ||
PDx Total Segment Costs & Expenses ($M)($M) | 593 | 593 | 573 | 556 | 529 | 516 | 428 | 433 | 432 | 439 | 421 | ||
PDx Segment Depreciation & Amortization ($M)($M) | 20 | 19 | 20 | 19 | 19 | 17 | 12 | 12 | 12 | 15 | 16 | ||
Other / HealthCare Financial Services Revenue ($M)($M)1 | 2 | 6 | 18 | 7 | 15 | 6 | 13 | 13 | 15 | 9 | 15 | 14 | |
Other / Unallocated Corporate Segment EBIT Impact ($M)($M) | -1 | 1 | 5 | 2 | 2 | 1 | 2 | 0 | 1 | 1 | -1 | -1 | |
United States & Canada (USCAN) Region Revenue ($M)($M)1 | 2,672 | 2,476 | 2,361 | 2,597 | 2,358 | 2,340 | 2,237 | 2,399 | 2,246 | 2,209 | 2,127 | 2,254 | |
USCAN Reported Revenue Growth (% YoY)(%) | 13.3% | 5.8% | 5.6% | 5.0% | 6.0% | 5.0% | 8.0% | 3.0% | 2.0% | ||||
Europe, Middle East & Africa (EMEA) Region Revenue ($M)($M)1 | 1,354 | 1,348 | 1,340 | 1,623 | 1,360 | 1,268 | 1,174 | 1,434 | 1,237 | 1,202 | 1,179 | 1,425 | |
EMEA Reported Revenue Growth (% YoY)(%) | -0.4% | 6.3% | 14.1% | 10.0% | 6.0% | 0.0% | -1.0% | -1.0% | 1.0% | ||||
China Region Revenue — Mainland China, Hong Kong, Macau & Taiwan ($M)($M)1 | 586 | 582 | 567 | 547 | 547 | 563 | 593 | 615 | 564 | 584 | 597 | 680 | |
China Region Reported Revenue Growth (% YoY)(%) | 7.1% | 3.4% | -4.4% | -3.0% | -4.0% | -1.0% | -22.0% | -18.0% | -11.0% | ||||
Rest of World Region Revenue — Asia-Pacific ex-China & Latin America ($M)($M)1 | 901 | 888 | 863 | 931 | 878 | 836 | 773 | 872 | 816 | 845 | 748 | 847 | |
Rest of World Reported Revenue Growth (% YoY)(%) | 2.6% | 6.3% | 11.6% | 8.0% | -1.0% | 3.0% | 5.0% | 13.0% | -5.0% | ||||
Total Company Organic Revenue Growth (% YoY)(%)4 | 6.2% | 3.5% | 2.9% | 4.8% | 3.5% | 1.7% | 4.1% | ||||||
Total Company Reported Revenue Growth (% YoY)(%) | 7.2% | 5.7% | 7.4% | 7.1% | 5.8% | 3.5% | 2.7% | ||||||
Total Company Organic Revenue Base ($M)($M) | 5,462 | 5,182 | 4,916 | 5,571 | 5,033 | 4,917 | 4,842 | ||||||
Total Company Foreign Exchange Revenue Impact ($M)($M) | -16 | 51 | 155 | 75 | 60 | 36 | -78 | ||||||
Total Company Acquisitions & Divestitures Revenue Impact ($M)($M) | 68 | 62 | 60 | 52 | 51 | 53 | 14 | ||||||
Total Contract & Other Deferred Assets ($M)($M)5 | 1,577 | 1,452 | 1,364 | 1,285 | 1,287 | 1,186 | 1,144 | 1,183 | 1,221 | 1,180 | 1,136 | 1,168 | |
Current Contract & Other Deferred Assets ($M)($M) | 1,365 | 1,235 | 1,159 | 1,073 | 1,069 | 978 | 953 | 974 | 1,033 | 994 | 961 | 1,000 | |
Current Contract Assets — Unbilled Equipment & Service Milestones ($M)($M) | 875 | 776 | 715 | 645 | 625 | 542 | 546 | 589 | 612 | 582 | 577 | 600 | |
Current Other Deferred Assets ($M)($M) | 489 | 459 | 444 | 428 | 444 | 436 | 407 | 385 | 421 | 412 | 384 | 400 | |
Noncurrent Contract Assets ($M)($M) | 87 | 91 | 84 | 91 | 98 | 92 | 83 | 103 | 90 | 90 | 78 | 72 | |
Noncurrent Other Deferred Assets ($M)($M) | 126 | 125 | 122 | 120 | 120 | 116 | 108 | 105 | 98 | 96 | 97 | 96 | |
Total Contract Liabilities — Deferred Revenue ($M)($M)6 | 3,147 | 3,057 | 2,972 | 2,899 | 2,777 | 2,720 | 2,613 | 2,629 | 2,619 | 2,562 | 2,566 | 2,623 | |
Current Contract Liabilities ($M)($M) | 2,251 | 2,200 | 2,153 | 2,095 | 2,002 | 1,979 | 1,889 | 1,943 | 1,915 | 1,876 | 1,879 | 1,918 | |
Noncurrent Contract Liabilities ($M)($M) | 895 | 857 | 819 | 803 | 775 | 741 | 724 | 686 | 704 | 685 | 687 | 705 | |
Revenue Recognized from Beginning Contract Liability Balance ($M)($M) | 280 | 406 | 783 | 203 | 251 | 382 | 752 | 204 | 265 | 375 | 741 | 197 | |
Current Customer Refund & Rebate Liabilities ($M)($M) | 141 | 103 | 87 | 148 | 118 | 133 | 151 | 153 | 135 | 126 | 136 | 144 | |
Current Sales Allowances & Related Liabilities ($M)($M) | 258 | 237 | 225 | 256 | 228 | 228 | 221 | 242 | 215 | 211 | 208 | 228 | |
Noncurrent Sales Allowances & Related Liabilities ($M)($M) | 29 | 26 | 25 | 23 | 23 | 27 | 24 | 23 | 23 | 23 | 24 | 27 | |
Total Inventories, Net of Reserves ($M)($M)4 | 2,628 | 2,483 | 2,353 | 2,234 | 2,304 | 2,283 | 2,158 | 1,939 | 2,124 | 2,023 | 1,989 | 1,960 | |
Raw Materials & Component Inventories ($M)($M) | 1,145 | 1,063 | 1,080 | 1,002 | 1,011 | 1,026 | 991 | 921 | 992 | 934 | 927 | 961 | |
Work in Process Inventories ($M)($M) | 118 | 103 | 104 | 95 | 101 | 93 | 99 | 92 | 100 | 102 | 101 | 91 | |
Finished Goods & Service Parts Inventories ($M)($M) | 1,365 | 1,317 | 1,170 | 1,137 | 1,191 | 1,164 | 1,068 | 926 | 1,032 | 987 | 961 | 908 | |
Noncurrent Inventories ($M)($M) | 143 | 127 | 122 | 121 | 140 | 145 | 143 | 139 | 151 | 149 | 154 | 147 | |
Current Customer & Other Receivables, Net ($M)($M)6 | 3,925 | 3,881 | 3,786 | 3,955 | 3,734 | 3,562 | 3,572 | 3,566 | |||||
Gross Current Trade Customer Receivables ($M)($M) | 3,609 | 3,535 | 3,465 | 3,719 | 3,474 | 3,337 | 3,379 | 3,382 | |||||
Allowance for Credit Losses on Current Receivables ($M)($M) | 101 | 102 | 100 | 103 | 108 | 107 | 106 | 103 | 104 | 103 | 102 | 98 | |
Current Non-Trade & Other Receivables ($M)($M) | 257 | 279 | 247 | 180 | 198 | 165 | 144 | 133 | |||||
Current Value-Added Tax (VAT) Receivables ($M)($M) | 160 | 169 | 174 | 159 | 170 | 167 | 155 | 155 | |||||
Noncurrent Financing & Customer Receivables, Net ($M)($M) | 170 | 183 | 187 | 190 | 189 | 191 | 161 | 142 | 167 | 153 | 130 | 124 | |
Confirmed Supplier Finance Program Obligations Outstanding ($M)($M) | 354 | 334 | 341 | 360 | 344 | 346 | 364 | 394 | 403 | 393 | 384 | 365 | |
Product Warranty Liability Balance ($M)($M)3 | 178 | 176 | 161 | 169 | 160 | 166 | 171 | 168 | 168 | 172 | 175 | 192 | |
Current Product Warranty Liability ($M)($M) | 178 | 176 | 161 | 169 | 160 | 166 | 171 | 168 | 168 | 172 | 175 | 192 | |
New Product Warranties Issued / Accrued ($M)($M) | 49 | 61 | 43 | 58 | 37 | 54 | 59 | 59 | 47 | 55 | 41 | 58 | |
Product Warranty Claims Paid / Settled ($M)($M) | 48 | 45 | 50 | 51 | 43 | 62 | 58 | 54 | 54 | 57 | 55 | 59 | |
Restructuring Reserve Liability Balance ($M)($M)7 | 99 | 109 | 111 | 92 | 89 | 76 | 89 | 86 | 80 | 76 | 76 | 68 | |
Restructuring Reserve — Workforce Severance ($M)($M) | 95 | 103 | 103 | 82 | 78 | 63 | 73 | 67 | 43 | ||||
Restructuring Reserve — Facility Exit & Site Closures ($M)($M) | 4 | 7 | 8 | 11 | 11 | 13 | 16 | 18 | 25 | ||||
Restructuring & Asset Impairment Charges Recognized ($M)($M) | 17 | 27 | 49 | 49 | 31 | 18 | 22 | 30 | 22 | 29 | 40 | 20 | |
Employee Severance & Related Restructuring Expense ($M)($M) | 16 | 25 | 44 | 38 | 30 | 12 | 21 | 24 | 19 | 17 | 25 | 12 | |
Facility Exit & Contract Termination Expense ($M)($M) | 0 | 2 | 3 | 5 | 1 | 1 | 0 | 3 | 2 | 5 | 8 | 1 | |
Cash Payments for Restructuring Actions ($M)($M) | 25 | 26 | 25 | 37 | 17 | 25 | 17 | ||||||
Expected Remaining Cost of Approved Restructuring Programs ($M)($M) | 21 | 38 | 25 | 53 | 24 | 34 | 40 | 36 | 21 | 16 | 25 | 20 | |
Property, Plant & Equipment, Gross ($M)($M)5 | 5,968 | 5,799 | 5,693 | 5,731 | 5,892 | 5,841 | 5,661 | 5,267 | 5,356 | 5,207 | 5,180 | 5,208 | |
Machinery, Manufacturing & Test Equipment, Gross ($M)($M) | 2,938 | 2,872 | 2,814 | 2,872 | 2,995 | 2,975 | 2,905 | 2,705 | 2,617 | ||||
Buildings, Structures & Related Equipment, Gross ($M)($M) | 2,255 | 2,207 | 2,155 | 2,140 | 2,191 | 2,199 | 2,107 | 1,943 | 1,956 | ||||
Leasehold Improvements & Manufacturing Plant Installations, Gross ($M)($M) | 633 | 582 | 582 | 574 | 556 | 516 | 503 | 553 | 565 | ||||
Land & Land Improvements, Gross ($M)($M) | 142 | 139 | 142 | 144 | 150 | 152 | 146 | 66 | 70 | ||||
Operating Lease Expense ($M)($M) | 59 | 60 | 63 | -49 | 63 | 60 | 62 | -55 | 70 | 59 | 60 | -46 | |
Adjusted EBIT ($M)($M)3 | 913 | 750 | 691 | 950 | 761 | 729 | 715 | 994 | 795 | 742 | 681 | 837 | |
Adjusted EBIT Margin (%)(%) | 16.6% | 14.2% | 13.5% | 16.7% | 14.8% | 14.6% | 15.0% | 18.7% | 16.3% | 15.3% | 14.7% | 16.1% | |
Amortization of Acquisition-Related Intangible Assets ($M)($M) | 61 | 61 | 47 | 40 | 41 | 40 | 35 | 37 | 34 | 35 | 31 | 32 | |
Acquisition & Disposition Related Costs / Benefits ($M)($M) | -11 | -11 | -35 | -15 | -9 | -7 | -8 | -10 | 4 | 3 | 0 | 0 | |
Adjusted Net Income ($M)($M)2 | 609 | 514 | 452 | 659 | 490 | 487 | 464 | 667 | 525 | 461 | 414 | 541 | |
GAAP Net Income Margin (%)(%) | 11.1% | 10.6% | 7.6% | 10.3% | 8.7% | 9.7% | 11.8% | 13.5% | 9.7% | 8.8% | 8.0% | 7.7% | |
Adjusted Diluted Earnings Per Share ($/share)($) | 1.34 | 1.13 | 0.99 | 1.44 | 1.07 | 1.06 | 1.01 | 1.45 | 1.14 | 1 | 0.90 | 1.18 | |
Free Cash Flow — Non-GAAP ($M)($M) | 793 | 45 | 135 | 916 | 483 | 7 | 98 | 811 | 651 | -182 | 274 | 956 | |
Redeemable Noncontrolling Interest Carrying Balance — Joint Ventures ($M)($M)3 | 234 | 229 | 218 | 209 | 204 | 220 | 211 | 188 | 177 | 177 | 177 | 165 | |
Net Income Attributable to Noncontrolling Interests ($M)($M) | 9 | 13 | 22 | 13 | 18 | 14 | 24 | 17 | 19 | 7 | 14 | 13 | |
Cash Paid for Business Acquisitions, Net of Cash Acquired ($M)($M) | 0 | -4 | 2,297 | 99 | 0 | 10 | 269 | 54 | 0 | 259 | 0 | 0 | |
Goodwill Added from Business Acquisitions ($M)($M) | 39 | 45 | 1,584 | 58 | 29 | -2 | 216 | 41 | 0 | 195 | 0 | 0 | |
FDA 510(k) Premarket Clearances Granted to GE HealthCare5 | 9 | 4 | 12 | 5 | 6 | 7 | 6 | 4 | 3 | 7 | 4 | 8 | |
U.S. MedTech Industry Total FDA 510(k) Clearances Granted | 855 | 923 | 756 | 806 | 797 | 886 | 736 | 856 | 767 | 793 | 713 | 877 | |
FDA Premarket Approval (PMA) Decisions & Supplements — GE HealthCare | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
U.S. MedTech Industry Total FDA PMA Decisions & Supplements | 565 | 608 | 567 | 525 | 585 | 588 | 524 | 683 | 538 | 550 | 459 | 656 | |
FDA Device Recall Events Posted — GE HealthCare | 16 | 25 | 10 | 31 | 30 | 22 | 43 | 24 | 34 | 14 | 8 | 5 | |
FDA Device Enforcement Reports — GE HealthCare | 17 | 25 | 9 | 31 | 32 | 25 | 38 | 27 | 36 | 9 | 8 | 7 | |
FDA MAUDE Medical Device Reports (MDRs) Received — GE HealthCare Total4 | 792 | 860 | 889 | 944 | 1,288 | 1,586 | 684 | 772 | 664 | 642 | 651 | 524 | |
FDA MAUDE Device Malfunction Reports — GE HealthCare | 779 | 845 | 856 | 926 | 1,278 | 1,562 | 659 | 753 | 647 | 633 | 638 | 502 | |
FDA MAUDE Serious Injury Reports — GE HealthCare | 10 | 15 | 32 | 17 | 9 | 22 | 21 | 18 | 16 | 9 | 12 | 21 | |
FDA MAUDE Death Reports — GE HealthCare | 0 | 0 | 1 | 1 | 1 | 2 | 2 | 0 | 1 | 0 | 1 | 0 | |
U.S. MedTech Industry Total FDA MAUDE Adverse Event Reports | 1,189,467 | 923,529 | 811,618 | 751,012 | 819,444 | 632,296 | 685,251 | 709,498 | 699,798 | 631,546 | 586,309 | 573,619 | |
Cumulative ClinicalTrials.gov Studies Sponsored by GE HealthCare1 | |||||||||||||
New Clinical Studies Initiated by GE HealthCare | 7 | 5 | 5 | 3 | 4 | 5 | 6 | 2 | 3 | 5 | 3 | 4 | |
U.S. Federal Government Prime Contract Obligations Awarded to GE HealthCare ($M)($M) | 7.96 | 12.4 | 1.95 | 4.72 | 14.7 | 30.8 | 3.40 | 4.03 | 21.8 | 0.21 | 10.6 | 5.10 | |
U.S. Industrial Production Index: Medical Equipment & Supplies (NAICS 3391, Index 2017=100)2 | |||||||||||||
U.S. Producer Price Index: Surgical & Medical Instruments (Index)(×) | 163.40 | 162.90 | 161.70 | 159.60 | 157.80 | 156.90 | 157.10 | 155.20 | 154.40 | 154.10 | 153.60 | 151.00 | |
U.S. CPI: Medical Care Services (Index 1982–84=100)(×) | 654.70 | 650.90 | 647.60 | 638.40 | 630.60 | 623.40 | 619.60 | 613.00 | 611.40 | 605.80 | 597.90 | ||
Total Consolidated Revenues ($M)($M) | 5,513 | 5,295 | 5,131 | 5,698 | 5,143 | 5,007 | 4,777 | 5,319 | 4,863 | 4,839 | 4,650 | 5,206 | |
Consolidated Gross Profit ($M)($M)2 | 2,224 | 2,180 | 1,977 | 2,261 | 1,990 | 1,985 | 2,012 | 2,275 | 2,026 | 2,002 | 1,902 | 2,156 | |
Cost of Products ($M)($M) | 2,373 | 2,217 | 2,283 | 2,550 | 2,270 | 2,160 | 1,963 | 2,226 | 2,033 | 2,045 | 1,967 | 2,268 | |
Cost of Services ($M)($M) | 916 | 898 | 871 | 887 | 884 | 863 | 802 | 818 | 805 | 792 | 782 | 782 | |
Consolidated Operating Income ($M)($M)8 | 805 | 739 | 515 | 827 | 653 | 654 | 629 | 801 | 676 | 608 | 540 | 689 | |
Research & Development Expense ($M)($M) | 320 | 323 | 345 | 323 | 292 | 302 | 344 | 344 | 316 | 327 | 324 | 315 | |
Selling, General & Administrative Expense ($M)($M) | 1,100 | 1,118 | 1,117 | 1,111 | 1,045 | 1,029 | 1,040 | 1,130 | 1,034 | 1,067 | 1,038 | 1,152 | |
Total Operating Expenses ($M)($M) | 1,419 | 1,441 | 1,462 | 1,434 | 1,337 | 1,331 | 1,383 | 1,474 | 1,350 | 1,395 | 1,362 | 1,467 | |
Income Before Income Taxes ($M)($M) | 752 | 693 | 505 | 821 | 643 | 613 | 692 | 834 | 658 | 578 | 512 | 609 | |
Provision for Income Taxes ($M)($M) | 129 | 119 | 94 | 219 | 179 | 113 | 104 | 96 | 168 | 143 | 124 | 193 | |
Net Income Attributable to GE HealthCare ($M)($M) | 615 | 561 | 389 | 589 | 446 | 486 | 564 | 721 | 470 | 428 | 374 | 403 | |
GAAP Diluted Earnings Per Share ($/share)($) | 1.36 | 1.24 | 0.85 | 1.29 | 0.98 | 1.06 | 1.23 | 1.57 | 1.02 | 0.93 | 0.81 | 0.88 | |
Weighted-Average Diluted Shares Outstanding (Millions)(M) | 453 | 454 | 457 | 0 | 457 | 458 | 459 | 0 | 459 | 459 | 459 | 0 | |
Total Assets ($M)($M)6 | 38,371 | 37,246 | 37,125 | 36,906 | 36,127 | 35,500 | 33,586 | 33,089 | 33,855 | 31,852 | 32,208 | 32,454 | |
Cash, Cash Equivalents & Restricted Cash ($M)($M) | 2,826 | 2,079 | 2,261 | 4,492 | 4,030 | 3,766 | 2,476 | 2,893 | 3,572 | 2,018 | 2,565 | 2,506 | |
Total Current Assets ($M)($M) | 11,495 | 10,497 | 10,426 | 12,501 | 11,893 | 11,308 | 9,735 | 9,901 | 10,638 | 8,806 | 9,373 | 9,410 | |
Property, Plant & Equipment, Net ($M)($M) | 3,219 | 3,146 | 3,095 | 3,092 | 3,010 | 2,962 | 2,851 | 2,550 | 2,539 | 2,458 | 2,445 | 2,144 | |
Goodwill ($M)($M) | 15,140 | 15,095 | 15,060 | 13,489 | 13,441 | 13,417 | 13,373 | 13,136 | 13,138 | 13,116 | 12,927 | 12,936 | |
Other Intangible Assets, Net ($M)($M) | 1,812 | 1,894 | 1,908 | 1,130 | 1,163 | 1,220 | 1,238 | 1,078 | 1,132 | 1,195 | 1,174 | 1,253 | |
Operating Lease Right-of-Use Assets ($M)($M) | 383 | 391 | 396 | 410 | 409 | 386 | 369 | 364 | 359 | 359 | 354 | 356 | |
Total Liabilities ($M)($M)7 | 26,508 | 26,027 | 26,227 | 26,307 | 25,907 | 25,548 | 24,168 | 24,437 | 25,343 | 23,858 | 24,609 | 25,144 | |
Total Current Liabilities ($M)($M) | 8,815 | 8,302 | 8,529 | 9,105 | 10,073 | 9,748 | 9,969 | 9,553 | 8,670 | 8,318 | 8,859 | 8,981 | |
Accounts Payable ($M)($M) | 3,320 | 3,231 | 3,410 | 3,250 | 2,987 | 2,975 | 3,152 | 3,035 | 2,911 | 2,824 | 2,931 | 2,947 | |
Short-Term Borrowings & Current Portion of Long-Term Debt ($M)($M) | 3 | 2 | 7 | 508 | 2,005 | 2,005 | 2,002 | 1,502 | 1,007 | 1,007 | 1,008 | 1,006 | |
Long-Term Borrowings ($M)($M) | 9,970 | 10,091 | 10,127 | 9,495 | 8,277 | 8,270 | 6,757 | 7,449 | 9,306 | 8,233 | 8,247 | 8,436 | |
Total Operating Lease Liabilities ($M)($M) | 382 | 394 | 402 | 419 | 419 | 398 | 386 | 385 | 378 | 380 | 376 | 383 | |
Noncurrent Pension & Postretirement Benefit Liabilities ($M)($M) | 5,107 | 5,186 | 5,300 | 5,453 | 5,287 | 5,351 | 5,443 | 5,583 | 5,388 | 5,455 | 5,625 | 5,782 | |
Total Stockholders' Equity Attributable to GE HealthCare ($M)($M) | 11,614 | 10,975 | 10,668 | 10,379 | 9,993 | 9,712 | 9,187 | 8,446 | 8,317 | 7,801 | 7,408 | 7,133 | |
Cash Flows from Operating Activities ($M)($M)8 | 907 | 168 | 290 | 1,050 | 593 | 94 | 250 | 913 | 742 | -119 | 419 | 1,050 | |
Additions to Property, Plant & Equipment and Internal-Use Software ($M)($M) | 114 | 100 | 178 | 134 | 110 | 86 | 152 | 102 | 90 | 64 | 145 | 94 | |
Share-Based Compensation Expense ($M)($M) | 36 | 45 | 35 | 36 | 38 | 34 | 22 | 33 | 22 | 36 | 34 | 33 | |
Cash Dividends Paid to Stockholders ($M)($M) | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 14 | 13 | 14 | 14 | 13 | |
Common Stock Dividends Declared Per Share ($/share)($) | 0.04 | 0.04 | 0.04 | 0.04 | 0.07 | 0 | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 | 0.03 | |
Cash Income Taxes Paid, Net ($M)($M) | 70 | 139 | 92 | 76 | 83 | 179 | 91 | 116 | 88 | 201 | 86 | 99 | |
Cash Interest Paid ($M)($M) | 84 | 193 | 87 | 195 | 67 | 182 | 78 | 211 | 65 | 219 | 55 | 252 | |
Cash Flows from Investing Activities ($M)($M) | -111 | -115 | -2,500 | -269 | -148 | -223 | -407 | -240 | -137 | -349 | -188 | -88 | |
Cash Flows from Financing Activities ($M)($M) | -40 | -236 | 21 | -293 | -165 | 1,361 | -286 | -1,277 | 914 | -57 | -153 | -900 | |
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Core Commercial & Operational Drivers (Groups 1–3): Total Company Book-to-Bill Ratio (x), Organic Orders Growth (% YoY), Total Ending Backlog ($B) and YoY Backlog Dollar Change ($B), Remaining Performance Obligations (RPO $M split between Products and Services), granular product sub-segment revenues (Radiology, Procedural Guidance, Specialized Ultrasound, Monitoring Solutions, Life Support Solutions, and PDx) continuously reconciled across the October 2024 (AVS) and July 2026 (AIS) Form 8-K recast filings, and four-region customer revenues (USCAN, EMEA, China region, and Rest of World).
- Parent-Only vs. Consolidated Financial Statements: GE HealthCare Technologies Inc. files under U.S. GAAP (Form 10-K / Form 10-Q) without separate parent-company-only Schedule I financial statements because restricted net assets of consolidated subsidiaries do not exceed 25% of consolidated net assets. Subsidiary and joint venture operations are captured directly from explicit disclosures in Group 7 (Exhibit 21.1 subsidiary counts by jurisdiction, redeemable noncontrolling interest balances and net income, M&A cash deployment, and UK statutory filings for GE Healthcare Limited and GE Medical Systems Limited).
- Derived Period Splitting: Quarterly values for fourth-quarter geographic revenues, segment cost disaggregation, and cash flow / footnote rollforward items reported on a cumulative year-to-date basis in Form 10-Q and Form 10-K are derived strictly via Q2 = 6M − Q1, Q3 = 9M − 6M, and Q4 = FY − 9M.
Không hiện vì thiếu các kỳ gần đây (20)
- Orders, Book-to-Bill, Backlog & Remaining Performance Obligations (Core Commercial Drivers) › Total Remaining Performance Obligations — RPO ($M) › Products Remaining Performance Obligations ($M) › Products RPO Expected to Be Recognized Within 2 Years (%)
- Orders, Book-to-Bill, Backlog & Remaining Performance Obligations (Core Commercial Drivers) › Total Remaining Performance Obligations — RPO ($M) › Services Remaining Performance Obligations ($M) › Services RPO Expected to Be Recognized Within 2 Years (%)
- Orders, Book-to-Bill, Backlog & Remaining Performance Obligations (Core Commercial Drivers) › Total Remaining Performance Obligations — RPO ($M) › Services Remaining Performance Obligations ($M) › Services RPO Expected to Be Recognized Within 5 Years (%)
- Sub-Segment & Segment Operations (Radiology, Procedural Guidance, Specialized Ultrasound, PDx & PCS) › Advanced Imaging & Solutions (AIS) Segment Revenue ($M) › AIS Segment EBIT ($M) › AIS Segment EBIT Margin (%)
- Sub-Segment & Segment Operations (Radiology, Procedural Guidance, Specialized Ultrasound, PDx & PCS) › Legacy Segment Structure — Advanced Visualization Solutions (AVS) Revenue ($M, Prior to Q2 2026 AIS Realignment) › Legacy AVS Segment EBIT ($M, Prior to Q2 2026 AIS Realignment)
- Sub-Segment & Segment Operations (Radiology, Procedural Guidance, Specialized Ultrasound, PDx & PCS) › Legacy Segment Structure — Advanced Visualization Solutions (AVS) Revenue ($M, Prior to Q2 2026 AIS Realignment) › Legacy Imaging Segment EBIT ($M, Prior to Q2 2026 AIS Realignment)
- Sub-Segment & Segment Operations (Radiology, Procedural Guidance, Specialized Ultrasound, PDx & PCS) › Legacy Segment Structure — Advanced Visualization Solutions (AVS) Revenue ($M, Prior to Q2 2026 AIS Realignment)
- Workforce, Commercial, R&D & Manufacturing Footprint, Supply Chain & Governance (10-K, Form SD, DEF 14A) › Total Global Employees / Colleagues › United States Employees
- Workforce, Commercial, R&D & Manufacturing Footprint, Supply Chain & Governance (10-K, Form SD, DEF 14A) › Total Global Employees / Colleagues › China Region Employees
- Workforce, Commercial, R&D & Manufacturing Footprint, Supply Chain & Governance (10-K, Form SD, DEF 14A) › Total Global Employees / Colleagues › U.S. Union-Represented Manufacturing Employees
- Contract Assets & Liabilities, Working Capital, Warranty, Restructuring & Lease Footnotes (Note 2 & XBRL) › Property, Plant & Equipment, Gross ($M) › Unrecorded Unconditional Purchase Obligations — Total Committed ($M)
- Contract Assets & Liabilities, Working Capital, Warranty, Restructuring & Lease Footnotes (Note 2 & XBRL) › Property, Plant & Equipment, Gross ($M) › Unconditional Purchase Obligations Due Within 1 Year ($M)
- Global Installed Base (over 4 million / over 5 million imaging, mobile diagnostics, and monitoring units globally) — Disclosed only as a lower-bound figure ('over 4 million' / 'more than 5 million') rather than an exact point count.
- Segment Installed Base Approximations (~400,000 Imaging systems and ~400,000 Ultrasound systems) — Disclosed only once in the 2022 Form 10-12B/A Spin-Off Information Statement without multi-year updates.
- Customers Served in Over 160 Countries and Approximately 1 Billion Patients Served Annually — Disclosed only as lower-bound marketing approximations ('over 160 countries', 'approximately 1 billion patients').
- AI-Enabled Device Authorizations (over 100 / 115+ FDA 510(k) AI-enabled clearances) — Disclosed only as cumulative lower-bound milestones in promotional highlights; exact period-by-period 510(k) clearances are captured directly from the U.S. FDA openFDA database.
- Recurring Revenue Share of Total Revenue (more than 45% in FY2024) — Disclosed only as a lower-bound percentage ('more than 45%') on the Q4 2024 earnings call.
- The Spirit & The Letter Code of Conduct Training Completion for FY2025 (>99.9%) — FY2025 value disclosed as a lower bound ('>99.9%'), leaving only FY2022–FY2024 point values without the latest completed fiscal year.
- Total Facility Waste Generated, Hazardous Waste, and Non-Hazardous Waste Recycling Breakdown (40,966 mt total, 2,701 mt hazardous, 38,265 mt non-hazardous in FY2025) — First disclosed in the 2025 Sustainability Report with only 1 year (FY2025) of history.
- Employee Engagement Survey Completion and Glint Engagement Score (75% in FY2023, 64%/75% in FY2024, pulse survey in FY2025) — Discontinued annual full-population survey format in FY2025 in favor of random pulse surveys.
Dữ liệu cập nhật 2026-11-07.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Orders, Book-to-Bill, Backlog & Remaining Performance Obligations (Core Commercial Drivers)
Sub-Segment & Segment Operations (Radiology, Procedural Guidance, Specialized Ultrasound, PDx & PCS)
Regional Revenues (USCAN, EMEA, China Region & Rest of World) & Organic Revenue Growth Bridge
- United States & Canada (USCAN) Region Revenue ($M) ($M)19 kỳ
- Europe, Middle East & Africa (EMEA) Region Revenue ($M) ($M)19 kỳ
- China Region Revenue — Mainland China, Hong Kong, Macau & Taiwan ($M) ($M)19 kỳ
- Rest of World Region Revenue — Asia-Pacific ex-China & Latin America ($M) ($M)19 kỳ
- Total Company Organic Revenue Growth (% YoY) (%)7 kỳ
Workforce, Commercial, R&D & Manufacturing Footprint, Supply Chain & Governance (10-K, Form SD, DEF 14A)
Contract Assets & Liabilities, Working Capital, Warranty, Restructuring & Lease Footnotes (Note 2 & XBRL)
- Total Contract & Other Deferred Assets ($M) ($M)17 kỳ
- Total Contract Liabilities — Deferred Revenue ($M) ($M)16 kỳ
- Total Inventories, Net of Reserves ($M) ($M)16 kỳ
- Current Customer & Other Receivables, Net ($M) ($M)10 kỳ
- Product Warranty Liability Balance ($M) ($M)21 kỳ
- Restructuring Reserve Liability Balance ($M) ($M)16 kỳ
- Property, Plant & Equipment, Gross ($M) ($M)16 kỳ
Non-GAAP Profitability, Free Cash Flow Conversion & Special Items Reconciliations
Subsidiaries, Joint Ventures, M&A Activity & UK Statutory Filings (Exhibit 21.1, Note 16 & UK Gov)
- Principal Consolidated Subsidiaries (Form 10-K Exhibit 21.1 Count)4 kỳ
- Redeemable Noncontrolling Interest Carrying Balance — Joint Ventures ($M) ($M)21 kỳ
- GE Healthcare Limited (UK #01002610) — Mean Hourly Gender Pay Gap (%) (%)9 kỳ
- GE Medical Systems Limited (UK #00252567) — Mean Hourly Gender Pay Gap (%) (%)9 kỳ
Sustainability, Workforce Safety, Product Quality, Circularity & Supplier Audits (ESG Reports)
- Total Recordable Injury & Illness Rate — TRIR (per 100 full-time workers) (×)4 kỳ
- Voluntary Attrition Rate — Professional Band & Above (%) (%)4 kỳ
- Total Operational GHG Emissions — Scope 1 + Scope 2 Market-Based (thousand mtCO2e)4 kỳ
- Total Operational Energy Consumption (MWh)4 kỳ
- Recovered Imaging & Ultrasound Systems & Parts Weight — Total (metric tons)3 kỳ
- FDA Facility Inspections Resulting in Form 483 Observations4 kỳ
- Global Supplier Responsibility Governance (SRG) Audits Conducted4 kỳ
External MedTech Regulatory, Clinical, Federal Contracts & Industry Benchmarks (FDA, ClinicalTrials.gov, USAspending, FRED)
- FDA 510(k) Premarket Clearances Granted to GE HealthCare153 kỳ
- FDA MAUDE Medical Device Reports (MDRs) Received — GE HealthCare Total153 kỳ
- Cumulative ClinicalTrials.gov Studies Sponsored by GE HealthCare10 kỳ
- U.S. Federal Government Prime Contract Obligations Awarded to GE HealthCare ($M) ($M)129 kỳ
- U.S. Industrial Production Index: Medical Equipment & Supplies (NAICS 3391, Index 2017=100) (×)0 kỳ
Consolidated Financial & Segment Context (GAAP Statements & Footnotes)
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của GE HealthCare Technologies
- SEC Form 10-Q (filed 2026-10-28) ↗
- SEC Form 10-K (filed 2026-02-04) ↗
- esg_2025.txt, Appendix: Key Performance Indicators (p. 57) ↗
- SEC Form 8-K (filed 2026-10-28) ↗
- SEC Form 10-Q (filed 2026-10-28) ↗
- SEC Form 10-K (filed 2026-02-04) ↗
- SEC Form 8-K (filed 2026-07-29) — Exhibit 99 — Total Revenues by Segment (AIS Recast) ↗
- U.S. FDA openFDA Medical Device Database (fda_510k_company) ↗
- U.S. FDA openFDA Medical Device Database (fda_maude_total) ↗
- USAspending.gov Federal Award Database — GE HealthCare Technologies / GE Medical Systems ↗
- SEC Form 8-K (filed 2026-02-04) ↗
- transcript_2025Q4.txt, Prepared Remarks (CFO Jay Saccaro) ↗
See a number that looks wrong?